Cash-rich Piramal picks up another 5.5 percent in Vodafone
February 4th, 2012 - 5:38 pm ICT by IANSNew Delhi, Feb 4 (IANS) Piramal Healthcare Saturday announced it would buy a 5.5 percent stake in Vodafone India for Rs.3,007 crore ($618 million), taking the total stake of the cash-rich drug manufacturer in the mobile telecom firm to 11 percent.
Sitting on a huge cash pile after selling off one of its domestic drug formulation to US pharmaceuticals major Abbott, the Ajay Piramal-led firm had bought a 5.5 percent stake in Vodafone last year.
“The transaction follows the settlement between Vodafone and Essar over sale of Essar’s approximately 33 percent stake in Vodafone India announced in July 2011 and the purchase by Piramal of approximately 5.5 percent of the issued share capital of Vodafone India from Essar in August 2011,” Piramal Healthcare said in a regulatory statement.
Piramal Healthcare, the flagship company of the Piramal group, had decided to venture into other sectors, after selling its formulation business to Abbott for about Rs.17,000 crore in 2010.
The company has already entered the financial services sector with the acquisition of private equity firms IndiaReit Fund Advisors and IndiaReit Investment Managers.
About its latest hike in stake in Vodafone, the company said, “The transaction contemplates various exit mechanisms for Piramal, including both participation in a potential initial public offering of Vodafone India and a sale of its stake to Vodafone.”
- Pirmal Healthcare scrip up 1.62 percent day after Vodafone deal - Aug 11, 2011
- Piramal concludes sale of formulations business to Abott - Sep 08, 2010
- Abbott to buy Piramal's branded drugs business for $3.71 bn (Roundup) - May 21, 2010
- Abbott to buy Piramal's branded drugs business for $3.71 bn (Lead) - May 21, 2010
- Vodafone to buy out Essar's stake in Indian subsidiary for $5 bn - Mar 31, 2011
- Piramal, Baxter settle patent issue - Nov 01, 2011
- Government studying court ruling on Vodafone tax dispute - Jan 25, 2012
- India's apex court saves Vodafone $2.2-bn tax burden (Roundup) - Jan 20, 2012
- Government's plea for Vodafone verdict review dismissed (Lead) - Mar 20, 2012
- Government seeks review of Supreme Court's Vodafone verdict (Lead) - Feb 18, 2012
- Piramal sells healthcare business to US firm - May 21, 2010
- Faced with 500 m pound license bill, Vodafone might take till 2020 to make Indian business turnaroun - Dec 01, 2010
- Abbott Labs pays 3.7 bn dollars to buy into Mumbai's Piramal Healthcare - May 22, 2010
- Vodafone tax verdict to impact on similar merger deals: experts - Jan 20, 2012
- Government seeks review of Supreme Court's Vodafone verdict - Feb 17, 2012
Tags: abbott, ajay, cash pile, drug formulation, drug manufacturer, financial services sector, flagship company, initial public offering, investment managers, mechanisms, mobile telecom, New Delhi, percent stake, pharmaceuticals, piramal group, private equity firms, sectors, share capital, telecom firm, vodafone